Novel tools for prostate cancer prognosis, diagnosis, and follow-up

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Dimakakos, Andreas ^a   Armakolas, Athanasios ^a   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY PROSTATE CANCER ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; SOMATOMEDIN; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; PSCA PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SCREENING; FOLLOW UP; HUMAN; PROSTATE CANCER PROGNOSTIC TEST; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; MALE; METABOLISM; PHYSIOLOGIC MONITORING; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS;

ANTIGENS, NEOPLASM; GPI-LINKED PROTEINS; HUMANS; MALE; MONITORING, PHYSIOLOGIC; NEOPLASM PROTEINS; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901809934     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/890697     Document Type: Review

References (121)

1. Baade P. D., Youlden D. R., Krnjacki L. J., International epidemiology of prostate cancer: geographical distribution and secular trends. Molecular Nutrition and Food Research 2009 53 2 171 184 2-s2.0-60849105360 10.1002/mnfr.200700511
2. Thalmann G. N., Anezinis P. E., Chang S.-M., Zhau H. E., Kim E. E., Hopwood V. L., Pathak S., von Eschenbach A. C., Chung L. W. K., Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Research 1994 54 10 2577 2581 2-s2.0-0028272478 (Pubitemid 24173741)
3. Klein E. A., Opportunities for prevention of prostate cancer: genetics, chemoprevention, and dietary intervention. Reviews in Urology 2002 5 SUPPLEMENT 4 S18 S28
4. Thompson I. M., PSA: a biomarker for disease. A biomarker for clinical trials. How useful is it? Journal of Nutrition 2006 136 10 2704 2-s2.0-33749484663
5. Stenman U. H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., Alfthan O., A complex between prostate-specific antigen and α 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Research 1991 51 1 222 226 2-s2.0-0026027671
6. Andriole G. L. Jr., PSA screening and prostate cancer risk reduction. Urologic Oncology 2012 30 6 936 937
7. Barry M. J., Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology 2001 58 SUPPLEMENT 6 25 32 2-s2.0-0035652778 10.1016/S0090-4295(01)01300-0 (Pubitemid 34007595)
8. Schröder F. H., PSA screening-a review of recent studies. European Journal of Cancer 2009 45 1 402 404 2-s2.0-70349104584 10.1016/S0959-8049(09) 70065-6
9. Thompson I. M., Chi C., Ankerst D. P., Goodman P. J., Tangen C. M., Lippman S. M., Lucia M. S., Parnes H. L., Coltman C. A., Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. Journal of the National Cancer Institute 2006 98 16 1128 1133 2-s2.0-33747407318 10.1093/jnci/djj307 (Pubitemid 44288787)
10. Mikolajczyk S. D., Rittenhouse H. G., Pro PSA: A more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio Journal of Medicine 2003 52 2 86 91 2-s2.0-0037931478 (Pubitemid 36834402)
11. Sharma S.,. Tumor markers in clinical practice: general principles and guidelines. Indian journal of medical and paediatric oncology. Official Journal of Indian Society of Medical & Paediatric Oncology 2009 30 1 1 8
12. Varambally S., Yu J., Laxman B., Rhodes D. R., Mehra R., Tomlins S. A., Shah R. B., Chandran U., Monzon F. A., Becich M. J., Wei J. T., Pienta K. J., Ghosh D., Rubin M. A., Chinnaiyan A. M., Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005 8 5 393 406 2-s2.0-27644506613 10.1016/j.ccr.2005.10.001 (Pubitemid 41579834)
13. Bradford T. J., Tomlins S. A., Wang X., Chinnaiyan A. M., Molecular markers of prostate cancer. Urologic Oncology 2006 24 6 538 551 2-s2.0-33751326131 10.1016/j.urolonc.2006.07.004 (Pubitemid 44810016)
14. Shariat S. F., Semjonow A., Lilja H., Savage C., Vickers A. J., Bjartell A., Tumor markers in prostate cancer I: blood-based markers. Acta Oncologica 2011 50 SUPPLEMENT 1 61 75 2-s2.0-79957461212 10.3109/0284186X.2010.542174
15. Troyer J. K., Beckett M. L., Wright G. L. Jr., Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. International Journal of Cancer 1995 62 5 552 558 2-s2.0-0029154151 10.1002/ijc.2910620511
16. Ren J. Q., Chen Z. Q., Zheng L., Chen Q., Li H., Zhu H. G., Correlation study of expression levels of prostate-specific membrane antigen and prostate-specific antigen with Gleason score of prostate carcinoma. Zhonghua Zhong liu za zhi [Chinese journal of oncology] 2004 26 12 735 738 2-s2.0-26944488731
17. Murphy G. P., Kenny G. M., Ragde H., Wolfert R. L., Boynton A. L., Holmes E. H., Misrock S. L., Bartsch G., Klocker H., Pointner J., Reissigl A., McLeod D. G., Douglas T., Morgan T., Gilbaugh J. Jr., Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology 1998 51 SUPPLEMENT 5 89 97 2-s2.0-0031834798 10.1016/S0090-4295(98) 00082-X (Pubitemid 28267884)
18. Mhawech-Fauceglia P., Zhang S., Terracciano L., Sauter G., Chadhuri A., Herrmann F. R., Penetrante R., Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: An immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007 50 4 472 483 2-s2.0-33847319632 10.1111/j.1365-2559.2007.02635.x (Pubitemid 46328190)
19. Kurek R., Nunez G., Tselis N., Konrad L., Martin T., Roeddiger S., Aumüller G., Zamboglou N., Lin D. W., Tunn U. W., Renneberg H., Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clinical Cancer Research 2004 10 17 5808 5814 2-s2.0-4444269507 10.1158/1078-0432.CCR-1004-03 (Pubitemid 39180959)
20. Gong M. C., Chang S. S., Sadelain M., Bander N. H., Heston W. D. W., Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer and Metastasis Reviews 1999 18 4 483 490 2-s2.0-0033511652 10.1023/A:1006308826967 (Pubitemid 30365326)
21. Chu D. C., Chuang C. K., Liou Y. F., Tzou R. D., Lee H. C., Sun C. F., The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma. Annals of the New York Academy of Sciences 2004 1022 157 162 2-s2.0-3242664152 10.1196/annals.1318.026 (Pubitemid 38951598)
22. Zhigang Z., Wenlv S., Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer. Japanese Journal of Clinical Oncology 2004 34 7 414 419 (Pubitemid 43115305)
23. Gu Z., Thomas G., Yamashiro J., Shintaku I. P., Dorey F., Raitano A., Witte O. N., Said J. W., Loda M., Reiter R. E., Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000 19 10 1288 1296 2-s2.0-0034594917 (Pubitemid 30160621)
24. Paul B., Dhir R., Landsittel D., Hitchens M. R., Getzenberg R. H., Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Research 2005 65 10 4097 4100 2-s2.0-20144375228 10.1158/0008-5472.CAN-04-4523 (Pubitemid 40775646)
25. Varambally S., Dhanasekaran S. M., Zhou M., Barrette T. R., Kumar-Sinha C., Sanda M. G., Ghosh D., Pienta K. J., Sewalt R. G. A. B., Otte A. P., Rubin M. A., Chinnaiyan A. M., The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002 419 6907 624 629 2-s2.0-18644382388 10.1038/nature01075
26. Hienert G., Kirchheimer J. C., Pfluger H., Binder B. R., Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. Journal of Urology 1988 140 6 1466 1469 2-s2.0-20244364627
27. Miyake H., Hara I., Yamanaka K., Arakawa S., Kamidono S., Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. International Journal of Oncology 1999 14 3 535 541 2-s2.0-0033087688
28. Shariat S. F., Roehrborn C. G., McConnell J. D., Park S., Alam N., Wheeler T. M., Slawin K. M., Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. Journal of Clinical Oncology 2007 25 4 349 355 2-s2.0-33846978442 10.1200/JCO.2006.05.6853 (Pubitemid 350002982)
29. Yu J., Yu J., Mani R.-S., Cao Q., Brenner C. J., Cao X., Wang X., Wu L., Li J., Hu M., Gong Y., Cheng H., Laxman B., Vellaichamy A., Shankar S., Li Y., Dhanasekaran S. M., Morey R., Barrette T., Lonigro R. J., Tomlins S. A., Varambally S., Qin Z. S., Chinnaiyan A. M., An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010 17 5 443 454 2-s2.0-77952103123 10.1016/j.ccr.2010.03.018
30. Cerveira N., Ribeiro F. R., Peixoto A., Costa V., Henrique R., Jerónimo C., Teixeira M. R., TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006 8 10 826 832 2-s2.0-33749870551 10.1593/neo.06427 (Pubitemid 44564838)
31. Park K., Tomlins S. A., Mudaliar K. M., Chiu Y. L., Esgueva R., Mehra R., Suleman K., Varambally S., Brenner J. C., MacDonald T., Srivastava A., Tewari A. K., Sathyanarayana U., Nagy D., Pestano G., Kunju L. P., Demichelis F., Chinnaiyan A. M., Rubin M. A., Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010 12 7 590 598 2-s2.0-77954997528 10.1593/neo.10726
32. Van Leenders G. J., Boormans J. L., Vissers C. J., Hoogland A. M., Bressers A. A., Furusato B., Trapman J., Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Modern Pathology 2011 24 8 1128 1138 2-s2.0-79961031183 10.1038/modpathol.2011. 65
33. Gasi Tandefelt D., Boormans J., Hermans K., Trapman J., ETS fusion genes in prostate cancer. Endocrine-Related Cancer 2014 10.1530/ERC-13-0390
34. Hessels D., Smit F. P., Verhaegh G. W., Witjes J. A., Cornel E. B., Schalken J. A., Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clinical Cancer Research 2007 13 17 5103 5108 2-s2.0-34548863661 10.1158/1078-0432.CCR-07-0700 (Pubitemid 47502077)
35. Salami S. S., Schmidt F., Laxman B., Regan M. M., Rickman D. S., Scherr D., Bueti G., Siddiqui J., Tomlins S. A., Wei J. T., Chinnaiyan A. M., Rubin M. A., Sanda M. G., Combining urinary detection of TMPRSS2:ERG and CaP3 with serum PSA to predict diagnosis of prostate cancer. Urologic Oncology 2013 31 5 566 571 2-s2.0-79955957154 10.1016/j.urolonc.2011.04.001
36. Hessels D., Schalken J. A., Urinary biomarkers for prostate cancer: a review. Asian Journal of Andrology 2013 15 3 333 339
37. Truong L. D., Kadmon D., McCune B. K., Flanders K. C., Scardino P. T., Thompson T. C., Association of transforming growth factor- β 1 with prostate cancer: an immunohistochemical study. Human Pathology 1993 24 1 4 9 2-s2.0-0027511966 10.1016/0046-8177(93)90055-L (Pubitemid 23046665)
38. Thompson T. C., Truong L. D., Timme T. L., Kadmon D., McCune B. K., Flanders K. C., Scardino P. T., Park S. H., Transforming growth factor beta 1 as a biomarker for prostate cancer. Journal of cellular biochemistry Supplement 1992 16 54 61 2-s2.0-0027034841 (Pubitemid 23047970)
39. Ivanović V., Demajo M., Krtolica K., Krajnović M., Konstantinović M., Baltić V., Prtenjak G., Stojiljković B., Breberina M., Nes ković-Konstantinović Z., Nikolić- Vukosavljević D., Dimitrijević B., Elevated plasma TGF- β 1 levels correlate with decreased survival of metastatic breast cancer patients. Clinica Chimica Acta 2006 371 1-2 191 193 2-s2.0-33746701947 10.1016/j.cca.2006.02.027 (Pubitemid 44162899)
40. Grant C. M., Kyprianou N., Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression. Translational Andrology and Urology 2013 2 3 202 211
41. Samatov T. R., Tonevitsky A. G., Schumacher U., Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. Molecular Cancer 2013 12, article 107 10.1186/1476-4598-12-107
42. Shariat S. F., Shalev M., Menesses-Diaz A., Kim I. Y., Kattan M. W., Wheeler T. M., Slawin K. M., Preoperative plasma levels of transforming growth factor beta1 (TGF- β 1 strongly predict progression in patients undergoing radical prostatectomy. Journal of Clinical Oncology 2001 19 11 2856 2864 2-s2.0-0035367931 (Pubitemid 32538195)
43. Matuo Y., Nishi N., Takasuka H., Masuda Y., Nishikawa K., Isaacs J. T., Adams P. S., McKeehan W. L., Sato G. H., Production and significance of TGF- β in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma. Biochemical and Biophysical Research Communications 1990 166 2 840 847 2-s2.0-0025012692 10.1016/0006-291X(90)90886-R (Pubitemid 20049921)
44. Tan D., Wu X., Hou M., Lee S. O., Lou W., Wang J., Janarthan B., Nallapareddy S., Trump D. L., Gao A. G., Interleukin-6 polymorphism is associated with more aggressive prostate cancer. Journal of Urology 2005 174 2 753 756 2-s2.0-22144440465 10.1097/01.ju.0000168723.42824.40 (Pubitemid 40981649)
45. Giri D., Ozen M., Ittmann M., Interleukin-6 is an autocrine growth factor in human prostate cancer. American Journal of Pathology 2001 159 6 2159 2165 2-s2.0-0035180451 (Pubitemid 33104270)
46. Shariat S. F., Kattan M. W., Traxel E., Andrews B., Zhu K., Wheeler T. M., Slawin K. M., Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clinical Cancer Research 2004 10 6 1992 1999 2-s2.0-1642392553 10.1158/1078-0432.CCR-0768-03 (Pubitemid 38375558)
47. Voulgari A., Pintzas A., Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochimica et Biophysica Acta 2009 1796 2 75 90 2-s2.0-70349165716 10.1016/j.bbcan.2009.03.002
48. Gravdal K., Halvorsen O. J., Haukaas S. A., Akslen L. A., A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clinical Cancer Research 2007 13 23 7003 7011 2-s2.0-37249030356 10.1158/1078-0432.CCR-07-1263 (Pubitemid 350276881)
49. Sethi S., Macoska J., Chen W., Sarkar F. H., Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. The American Journal of Translational Research 2011 3 1 90 99 2-s2.0-78650223132
50. Anose B. M., Lagoo L., Schwendinger J., Characterization of androgen regulation of ZEB-1 and PSA in 22RV1 prostate cancer cells. Advances in Experimental Medicine and Biology 2008 617 541 546 2-s2.0-46749094254 10.1007/978-0-387-69080-3-55
51. Armstrong A. J., Marengo M. S., Oltean S., Kemeny G., Bitting R. L., Turnbull J. D., Herold C. I., Marcom P. K., George D. J., Garcia-Blanco M. A., Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research 2011 9 8 997 1007 2-s2.0-80051988763 10.1158/1541-7786.MCR-10-0490
52. Lukyanchuk V. V., Friess H., Kleeff J., Osinsky S. P., Ayuni E., Candinas D., Roggo A., Detection of circulating tumor cells by cytokeratin 20 and prostate stem cell antigen RT-PCR in blood of patients with gastrointestinal cancers. Anticancer Research 2003 23 3 2711 2716 2-s2.0-0041304837 (Pubitemid 36897148)
53. Camara O., Rengsberger M., Egbe A., Koch A., Gajda M., Hammer U., Jörke C., Rabenstein C., Untch M., Pachmann K., The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Annals of Oncology 2007 18 9 1484 1492 2-s2.0-34548439929 10.1093/annonc/mdm206 (Pubitemid 47365480)
54. Armakolas A., Panteleakou Z., Nezos A., Tsouma A., Skondra M., Lembessis P., Pissimissis N., Koutsilieris M., Detection of the circulating tumor cells in cancer patients. Future Oncology 2010 6 12 1849 1856 2-s2.0-78650430304 10.2217/fon.10.152
55. Panteleakou Z., Lembessis P., Sourla A., Pissimissis N., Polyzos A., Deliveliotis C., Koutsilieris M., Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Molecular Medicine 2009 15 3-4 101 114 2-s2.0-64549101978 10.2119/molmed.2008. 00116
56. Thalgott M., Rack B., Maurer T., Detection of circulating tumor cells in different stages of prostate cancer. Journal of Cancer Research and Clinical Oncology 2013 139 5 755 763
57. ® is a predictor for relapse: a preliminary report. World Journal of Surgical Oncology 2005 3, article 18 2-s2.0-27444444117 10.1186/1477-7819-3- 18 (Pubitemid 41529284)
58. Pachmann K., Camara O., Kavallaris A., Krauspe S., Malarski N., Gajda M., Kroll T., Jörke C., Hammer U., Altendorf-Hofmann A., Rabenstein C., Pachmann U., Runnebaum I., Höffken K., Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. Journal of Clinical Oncology 2008 26 8 1208 1215 2-s2.0-41649098480 10.1200/JCO.2007.13.6523
59. Pollak M., Insulin, insulin-like growth factors and neoplasia. Best Practice and Research: Clinical Endocrinology and Metabolism 2008 22 4 625 638 2-s2.0-54349093798 10.1016/j.beem.2008.08.004
60. Gallagher E. J., LeRoith D., The proliferating role of insulin and insulin-like growth factors in cancer. Trends in Endocrinology and Metabolism 2010 21 10 610 618 2-s2.0-77957241580 10.1016/j.tem.2010.06.007
61. Werner H., Bruchim I., IGF-1 and BRCA1 signalling pathways in familial cancer. The Lancet Oncology 2012 13 12 e537 e544
62. Chan J. M., Stampfer M. J., Ma J., Gann P., Gaziano J. M., Pollak M., Giovannucci E., Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. Journal of the National Cancer Institute 2002 94 14 1099 1106 2-s2.0-0037125383 (Pubitemid 34830730)
63. Hellawell G. O., Turner G. D. H., Davies D. R., Poulsom R., Brewster S. F., Macaulay V. M., Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Research 2002 62 10 2942 2950 2-s2.0-0037092971 (Pubitemid 34525783)
64. Voskuil D. W., Bosma A., Vrieling A., Rookus M. A., Van 'T Veer L. J., Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Research and Treatment 2004 84 3 225 233 2-s2.0-1842430143 10.1023/B:BREA.0000019954.59130.d3 (Pubitemid 38445372)
65. Ryan C. J., Haqq C. M., Simko J., Nonaka D. F., Chan J. M., Weinberg V., Small E. J., Goldfine I. D., Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations 2007 25 2 134 140 2-s2.0-33847374107 10.1016/j.urolonc.2006.07.019 (Pubitemid 46349758)
66. Koliakos G., Chatzivasiliou D., Dimopoulos T., Trachana V., Paschalidou K., Galiamoutsas V., Triantos A., Chitas G., Dimopoulos A., Vlatsas G., The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer. Disease Markers 2000 16 3-4 143 146 2-s2.0-0034437042 (Pubitemid 32591571)
67. Carboni J. M., Lee A. V., Hadsell D. L., Rowley B. R., Lee F. Y., Bol D. K., Camuso A. E., Gottardis M., Greer A. F., Ho C. P., Hurlburt W., Li A., Saulnier M., Velaparthi U., Wang C., Wen M.-L., Westhouse R. A., Wittman M., Zimmermann K., Rupnow B. A., Wong T. W., Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Research 2005 65 9 3781 3787 2-s2.0-20944440088 10.1158/0008-5472.CAN-04- 4602 (Pubitemid 40616356)
68. Rosenzweig S. A., Atreya H. S., Defining the pathway to insulin-like growth factor system targeting in cancer. Biochemical Pharmacology 2010 80 8 1115 1124 2-s2.0-77956230328 10.1016/j.bcp.2010.06.013
69. King E. R., Wong K.-K., Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Patents on Anti-Cancer Drug Discovery 2012 7 1 14 30 2-s2.0-83455236504
70. Wang Y., Hailey J., Williams D., Wang Y., Lipari P., Malkowski M., Wang X., Xie L., Li G., Saha D., Ling W. L. W., Cannon-Carlson S., Greenberg R., Ramos R. A., Shields R., Presta L., Brams P., Bishop W. R., Pachter J. A., Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Molecular Cancer Therapeutics 2005 4 8 1214 1221 2-s2.0-23844521596 10.1158/1535-7163.MCT- 05-0048 (Pubitemid 41149569)
71. Calzone F. J., Cajulis E., Chung Y. A., Tsai M. M., Mitchell P., Lu J., Epitope-specific mechanisms of IGF1R inhibition by ganitumab. PLoS ONE 2013 8 2 e55135
72. Papatsoris A. G., Karamouzis M. V., Papavassiliou A. G., Novel insights into the implication of the IGF-1 network in prostate cancer. Trends in Molecular Medicine 2005 11 2 52 55 2-s2.0-13244281973 10.1016/j.molmed.2004.12. 005 (Pubitemid 40193482)
73. Pollak M. N., Schernhammer E. S., Hankinson S. E., Insulin-like growth factors and neoplasia. Nature Reviews Cancer 2004 4 7 505 518 2-s2.0-3042781558 (Pubitemid 38868620)
74. De Meyts P., Whittaker J., Structural biology of insulin and IGF1 receptors: implications for drug design. Nature Reviews Drug Discovery 2002 1 10 769 783 2-s2.0-0036782071 10.1038/nrd917 (Pubitemid 37361561)
75. García-Echeverría C., Pearson M. A., Marti A., Meyer T., Mestan J., Zimmermann J., Gao J., Brueggen J., Capraro H.-G., Cozens R., Evans D. B., Fabbro D., Furet P., Porta D. G., Liebetanz J., Martiny-Baron G., Ruetz S., Hofmann F., In vivo antitumor activity of NVP-AEW541-a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004 5 3 231 239 2-s2.0-12144285705 10.1016/S1535-6108(04)00051-0 (Pubitemid 38402115)
76. Bielen A., Perryman L., Box G. M., Valenti M., Brandon A. D. H., Martins V., Jury A., Popov S., Gowan S., Jeay S., Raynaud F. I., Hofmann F., Hargrave D., Eccles S. A., Jones C., Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFR α / β Molecular Cancer Therapeutics 2011 10 8 1407 1418 2-s2.0-80051597880 10.1158/1535-7163. MCT-11-0205
77. Arcaro A., Targeting the insulin-like growth factor-1 receptor in human cancer. Frontiers in Pharmacology 2013 4 30
78. Abraham J., Prajapati S. I., Nishijo K., Schaffer B. S., Taniguchi E., Kilcoyne A., McCleish A. T., Nelon L. D., Giles F. G., Efstratiadis A., LeGallo R. D., Nowak B. M., Rubin B. P., Malempati S., Keller C., Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Molecular Cancer Therapeutics 2011 10 4 697 707 2-s2.0-79955779350 10.1158/1535-7163.MCT-10-0695
79. Nilsson B. O., Carlsson L., Larsson A., Ronquist G., Autoantibodies to prostasomes as new markers for prostate cancer. Upsala Journal of Medical Sciences 2001 106 1 43 50 2-s2.0-0035756178 (Pubitemid 33674530)
80. Bradley S. V., Oravecz-Wilson K. I., Bougeard G., Mizukami I., Li L., Munaco A. J., Sreekumar A., Corradetti M. N., Chinnaiyan A. M., Sanda M. G., Ross T. S., Serum antibodies to Huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Research 2005 65 10 4126 4133 2-s2.0-20144366038 10.1158/0008-5472.CAN-04-4658 (Pubitemid 40775650)
81. Finn O. J., Immune response as a biomarker for cancer detection and a lot more. The New England Journal of Medicine 2005 353 12 1288 1290 2-s2.0-25144444158 10.1056/NEJMe058157 (Pubitemid 41345953)
82. Hansen J. E., Chan G., Liu Y., Targeting cancer with a lupus autoantibody. Science Translational Medicine 2012 4 157 157ra42
83. Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., Mehra R., Montie J. E., Pienta K. J., Sanda M. G., Kantoff P. W., Rubin M. A., Wei J. T., Ghosh D., Chinnaiyan A. M., Autoantibody signatures in prostate cancer. The New England Journal of Medicine 2005 353 12 1224 1235 2-s2.0-25144483466 10.1056/NEJMoa051931 (Pubitemid 41345944)
84. Reis B. S., Jungbluth A. A., Frosina D., Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clinical Cancer Research 2013 19 22 6112 6125
85. Zhu H., Bilgin M., Snyder M., Proteomics. Annual Review of Biochemistry 2003 72 783 812 2-s2.0-0041765832 10.1146/annurev.biochem.72.121801.161511 (Pubitemid 36930460)
86. Pin E., Fredolini C., Petricoin E. F. III, The role of proteomics in prostate cancer research: biomarker discovery and validation. Clinical Biochemistry 2013 46 6 524 538
87. Hathout Y., Approaches to the study of the cell secretome. Expert Review of Proteomics 2007 4 2 239 248 2-s2.0-34247133868 10.1586/14789450.4.2.239 (Pubitemid 46588459)
88. Trock B. J., Application of metabolomics to prostate cancer. Urologic Oncology 2011 29 5 572 581 2-s2.0-80052930281 10.1016/j.urolonc.2011.08.002
89. Roberts M. J., Schirra H. J., Lavin M. F., Gardiner R. A., Metabolomics: a novel approach to early and noninvasive prostate cancer detection. Korean Journal of Urology 2011 52 2 79 89 2-s2.0-79952502199 10.4111/kju.2011.52.2.79
90. Costello L. C., Franklin R. B., Concepts of citrate production and secretion by prostate 1. Metabolic relationships. Prostate 1991 18 1 25 46 2-s2.0-0026093087
91. Kumar V., Dwivedi D. K., Jagannathan N. R., High-resolution NMR spectroscopy of human body fluids and tissues in relation to prostate cancer. NMR in Biomedicine 2014 27 1 80 89
92. Struys E. A., Heijboer A. C., van Moorselaar J., Jakobs C., Blankenstein M. A., Serum sarcosine is not a marker for prostate cancer. Annals of Clinical Biochemistry 2010 47 3 282 2-s2.0-77951849434 10.1258/acb.2010.009270
93. Sreekumar A., Poisson L. M., Rajendiran T. M., Khan A. P., Cao Q., Yu J., Laxman B., Mehra R., Lonigro R. J., Li Y., Nyati M. K., Ahsan A., Kalyana-Sundaram S., Han B., Cao X., Byun J., Omenn G. S., Ghosh D., Pennathur S., Alexander D. C., Berger A., Shuster J. R., Wei J. T., Varambally S., Beecher C., Chinnaiyan A. M., Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009 457 7231 910 914 2-s2.0-60149091657 10.1038/nature07762
94. Pavlou M., Diamandis E. P., The search for new prostate cancer biomarkers continues. Clinical Chemistry 2009 55 7 1277 1279 2-s2.0-67650091465 10.1373/clinchem.2009.126870
95. Chen J., Zhang J., Zhang W., Chen Z., Sensitive determination of the potential biomarker sarcosine for prostate cancer by LC-MS with N, N′-dicyclohexylcarbodiimide derivatization. Journal of Separation Science 2014 37 1-2 14 19
96. Swanson M. G., Vigneron D. B., Tabatabai Z. L., Males R. G., Schmitt L., Carroll P. R., James J. K., Hurd R. E., Kurhanewicz J., Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magnetic Resonance in Medicine 2003 50 5 944 954 2-s2.0-0242353960 10.1002/mrm.10614 (Pubitemid 37356574)
97. Swanson M. G., Keshari K. R., Tabatabai Z. L., Simko J. P., Shinohara K., Carroll P. R., Zektzer A. S., Kurhanewicz J., Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using1H HR-MAS total correlation spectroscopy. Magnetic Resonance in Medicine 2008 60 1 33 40 2-s2.0-46849090979 10.1002/mrm.21647 (Pubitemid 351956607)
98. Kobus T., Wright A. J., Weiland E., Heerschap A., Scheenen T. W., Metabolite ratios in H MR spectroscopic imaging of the prostate. Magnetic Resonance in Medicine 2014 10.1002/mrm.25122
99. Yoneyama T., Tateishi U., Terauchi T., Inoue T., Correlation of metabolic tumor volume and C-choline uptake with the pathology of prostate cancer: evaluation by use of simultaneously recorded MR and PET images. Japanese Journal of Radiology 2014 32 3 155 163 10.1007/s11604-014-0283-3
100. Dobosy J. R., Roberts J. L. W., Fu V. X., Jarrard D. F., The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. Journal of Urology 2007 177 3 822 831 2-s2.0-33846854438 10.1016/j.juro.2006.10.063 (Pubitemid 46223571)
101. Jerónimo C., Bastian P. J., Bjartell A., Carbone G. M., Catto J. W. F., Clark S. J., Henrique R., Nelson W. G., Shariat S. F., Epigenetics in prostate cancer: biologic and clinical relevance. European Urology 2011 60 4 753 766 2-s2.0-80052260149 10.1016/j.eururo.2011.06.035
102. Chan T. A., Glockner S., Joo M. Y., Chen W., Van Neste L., Cope L., Herman J. G., Velculescu V., Schuebel K. E., Ahuja N., Baylin S. B., Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Medicine 2008 5 5, article e114 2-s2.0-44449094545 10.1371/journal.pmed.0050114 (Pubitemid 351760910)
103. Wu T., Giovannucci E., Welge J., Mallick P., Tang W.-Y., Ho S.-M., Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: A meta-analysis. British Journal of Cancer 2011 105 1 65 73 2-s2.0-79959686697 10.1038/bjc.2011.143
104. Nakayama M., Bennett C. J., Hicks J. L., Epstein J. I., Platz E. A., Nelson W. G., De Marzo A. M., Hypermethylation of the human glutathione S-transferase- π gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. The American Journal of Pathology 2003 163 3 923 933 2-s2.0-0041924823 (Pubitemid 37040128)
105. Li L. C., Okino S. T., Dahiya R., DNA methylation in prostate cancer. Biochimica et Biophysica Acta 2004 1704 2 87 102 2-s2.0-4444352815 10.1016/j.bbcan.2004.06.001 (Pubitemid 39195351)
106. Enokida H., Shiina H., Urakami S., Igawa M., Ogishima T., Li L.-C., Kawahara M., Nakagawa M., Kane C. J., Carroll P. R., Dahiya R., Multigene methylation analysis for detection and staging of prostate cancer. Clinical Cancer Research 2005 11 18 6582 6588 2-s2.0-25144433754 10.1158/1078-0432.CCR- 05-0658 (Pubitemid 41338998)
107. Kawamoto K., Okino S. T., Place R. F., Urakami S., Hirata H., Kikuno N., Kawakami T., Tanaka Y., Pookot D., Chen Z., Majid S., Enokida H., Nakagawa M., Dahiya R., Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clinical Cancer Research 2007 13 9 2541 2548 2-s2.0-34249113234 10.1158/1078-0432.CCR-06-2225 (Pubitemid 46788019)
108. Chiam K., Ricciardelli C., Bianco-Miotto T., Epigenetic biomarkers in prostate cancer: current and future uses. Cancer Letters 2014 342 2 248 256 2-s2.0-84858710929 10.1016/j.canlet.2012.02.011
109. Schwarzenbach H., Hoon D. S. B., Pantel K., Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews Cancer 2011 11 6 426 437 2-s2.0-79957458567 10.1038/nrc3066
110. Seligson D. B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S. K., Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005 435 7046 1262 1266 2-s2.0-21744457108 10.1038/nature03672 (Pubitemid 40943093)
111. Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J. J., Lötvall J. O., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology 2007 9 6 654 659 2-s2.0-34249302620 10.1038/ncb1596 (Pubitemid 47214727)
112. Wang K., Zhang S., Weber J., Baxter D., Galas D. J., Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Research 2010 38 20 7248 7259 2-s2.0-78149409316 10.1093/nar/gkq601
113. Brase J. C., Wuttig D., Kuner R., Sültmann H., Serum microRNAs as non-invasive biomarkers for cancer. Molecular Cancer 2010 9, article 306 2-s2.0-78649325763 10.1186/1476-4598-9-306
114. Bryant R. J., Pawlowski T., Catto J. W. F., Marsden G., Vessella R. L., Rhees B., Kuslich C., Visakorpi T., Hamdy F. C., Changes in circulating microRNA levels associated with prostate cancer. British Journal of Cancer 2012 106 4 768 774 2-s2.0-84856812332 10.1038/bjc.2011.595
115. Osin P. P., Lakhani S. R., The pathology of familial breast cancer. Immunohistochemistry and molecular analysis. Breast Cancer Research 1999 1 1 36 40 2-s2.0-0033281493 10.1186/bcr11 (Pubitemid 32223534)
116. Berstein L. M., Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis. Future Oncology 2008 4 1 23 39 2-s2.0-39549108892 10.2217/14796694.4.1.23 (Pubitemid 351372604)
117. Eerola H., Heikkilä P., Tamminen A., Aittomäki K., Blomqvist C., Nevanlinna H., Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Research 2005 7 4 R465 R469 2-s2.0-33644801945
118. Barnett C. M., Heinrich M. C., Lim J., Nelson D., Beadling C., Warrick A., Genetic Profiling to Determine Risk of Relapse Free Survival in High-risk Localized Prostate Cancer. Clinical Cancer Research 2013 20 5 1306 1312 10.1158/1078-0432.CCR-13-1775
119. Schoenborn J. R., Nelson P., Fang M., Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clinical Cancer Research 2013 19 15 4058 4066
120. Hudson B. D., Kulp K. S., Loots G. G., Prostate cancer invasion and metastasis: insights from mining genomic data. Briefings in Functional Genomics 2013 12 5 397 410
121. Amaro A., Esposito A. I., Gallina A., Nees M., Angelini G., Albini A., Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel. Cancer and Metastasis Reviews 2014 10.1007/s10555-013-9470- 4